India's Roche Pharma has introduced Tecentriq, a groundbreaking seven-minute injection for treating non-small cell lung cancer (NSCLC) patients, significantly reducing treatment time compared to traditional intravenous methods. Priced at ₹3.7 lakh (approximately $4,500 USD) per dose, this innovative drug raises concerns regarding accessibility, as many patients require around six doses, leading to substantial overall costs. Tecentriq utilizes atezolizumab, which blocks the PD-L1 protein, allowing the immune system to effectively target cancer cells. This treatment is particularly beneficial for patients with high PD-L1 levels in their tumors, with experts estimating that nearly half of NSCLC patients may qualify. To address the financial burden, Roche has launched the 'Blue Tree' patient assistance program and included the drug under the Central Government Health Scheme (CGHS) for reimbursement support. Despite the high cost, doctors view this injection as a significant advancement in cancer care, improving patient comfort and treatment efficiency.